Therapy

Anti-HCV Core IgM Predict Long-Term IFN Response

Published in Hepatitis Weekly, May 24th, 1999

Hepatitis C virus antibody core immunoglobulin M levels may be sensitive predictors of long-term interferon response in patients with chronic hepatitis C infection.

In this study, C. Vandelli and colleagues evaluated the efficacy of a 12-month course of recombinant interferon (alpha) (IFN-(alpha)2b) and assessed predictive factors of successful response to IFN therapy in chronic active hepatitis C (HCV CAH) ("Prediction of Successful Outcome in a Randomized Controlled Trial of the Long-Term Efficacy of Interferon (alpha) Treatment for Chronic Hepatitis C," Journal of Medical Virology, May 1999;58(1):26-34).

A total of 242 patients with histologically...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (1999-05-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry